Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (11-20 of 231) with videos related to

Pageof 24
Sort By:
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab: positive data from a negative trialJose Perez-Garcia, Javier Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2018
Reply to K.S. Shohdy et alTiffany A Traina, Javier Cortes
The Lancet. Oncology|August 14, 2012
A roadmap for accelerated drug approval in breast cancer?Jose Perez-Garcia, Javier Cortes
Breast (Edinburgh, Scotland)|May 8, 2012
Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?Leticia De Mattos-Arruda, Javier Cortes
The New England Journal of Medicine|October 14, 2022
Pembrolizumab in Triple-Negative Breast Cancer. ReplyJavier Cortes, Xuan Zhou, Peter Schmid
The New England Journal of Medicine|May 4, 2022
Pembrolizumab in Early Triple-Negative Breast Cancer. ReplyPeter Schmid, Javier Cortes, Rebecca Dent
JAMA|April 9, 2009
Risk of venous thromboembolism with bevacizumab in cancer patientsJavier Cortes, Cristina Saura, Francesco Atzori
The Oncologist|April 24, 2012
Advances in first-line treatment for patients with HER-2+ metastatic breast cancerLeticia De Mattos-Arruda, Javier Cortes
Expert Opinion on Drug Safety|May 21, 2019
The safety of eribulin for the treatment of metastatic breast cancerJose Manuel Perez-Garcia, Javier Cortes
Advances in Therapy|July 25, 2013
Use of pertuzumab for the treatment of HER2-positive metastatic breast cancerLeticia De Mattos-Arruda, Javier Cortes
Pageof 24

Showing results (11-20 of 231) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab: positive data from a negative trialJose Perez-Garcia, Javier Cortes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2018
Reply to K.S. Shohdy et alTiffany A Traina, Javier Cortes
The Lancet. Oncology|August 14, 2012
A roadmap for accelerated drug approval in breast cancer?Jose Perez-Garcia, Javier Cortes
Breast (Edinburgh, Scotland)|May 8, 2012
Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?Leticia De Mattos-Arruda, Javier Cortes
The New England Journal of Medicine|October 14, 2022
Pembrolizumab in Triple-Negative Breast Cancer. ReplyJavier Cortes, Xuan Zhou, Peter Schmid
The New England Journal of Medicine|May 4, 2022
Pembrolizumab in Early Triple-Negative Breast Cancer. ReplyPeter Schmid, Javier Cortes, Rebecca Dent
JAMA|April 9, 2009
Risk of venous thromboembolism with bevacizumab in cancer patientsJavier Cortes, Cristina Saura, Francesco Atzori
The Oncologist|April 24, 2012
Advances in first-line treatment for patients with HER-2+ metastatic breast cancerLeticia De Mattos-Arruda, Javier Cortes
Expert Opinion on Drug Safety|May 21, 2019
The safety of eribulin for the treatment of metastatic breast cancerJose Manuel Perez-Garcia, Javier Cortes
Advances in Therapy|July 25, 2013
Use of pertuzumab for the treatment of HER2-positive metastatic breast cancerLeticia De Mattos-Arruda, Javier Cortes
Pageof 24